{"id":6794,"date":"2024-05-24T10:35:06","date_gmt":"2024-05-24T10:35:06","guid":{"rendered":"http:\/\/medexperts.pro\/?p=6794"},"modified":"2024-05-24T11:28:15","modified_gmt":"2024-05-24T11:28:15","slug":"ozempic-may-help-treat-kidney-disease-study-finds","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=6794","title":{"rendered":"Ozempic May Help Treat Kidney Disease, Study Finds"},"content":{"rendered":"
<\/div>\n

A major clinical trial showed such promising results that the drug\u2019s maker halted it early.<\/p>\n

\n
\n
\n

Semaglutide, the compound in the blockbuster drugs Ozempic<\/a> and Wegovy<\/a>, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic kidney disease in a major clinical trial, the results of which were published on Friday. The findings could transform how doctors treat some of the sickest patients with chronic kidney disease, which affects more than one in seven<\/a> adults in the United States but has no cure.<\/p>\n

\u201cThose of us who really care about kidney patients spent our whole careers wanting something better,\u201d said Dr. Katherine Tuttle, a professor of medicine at the University of Washington School of Medicine and an author of the study. \u201cAnd this is as good as it gets.\u201d The research was presented at a European Renal Association meeting in Stockholm on Friday and simultaneously published in The New England Journal of Medicine<\/a>.<\/p>\n

The trial, funded by Ozempic maker Novo Nordisk, was so successful that the company stopped it early<\/a>. Dr. Martin Holst Lange, Novo Nordisk\u2019s executive vice president of development, said that the company would ask the Food and Drug Administration to update Ozempic\u2019s label to say it can also be used to <\/span>reduce the progression of chronic kidney disease or complications in people with Type 2 diabetes.<\/p>\n

Diabetes is a leading cause<\/a> of chronic kidney disease, which occurs when the kidneys don\u2019t function as well as they should. In advanced stages, the kidneys are so damaged that they cannot properly filter blood. This can cause fluid and waste to build up in the blood, which can exacerbate high blood pressure and raise the risk of heart disease and stroke, said Dr. Subramaniam Pennathur, the chief of the nephrology division at Michigan Medicine.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

The study included 3,533 people with kidney disease and Type 2 diabetes, about half of whom took a weekly injection of semaglutide, and half of whom took a weekly placebo shot.<\/p>\n

Researchers followed up with participants after a median period of around three and a half years and found that those who took semaglutide had a 24 percent lower likelihood of having a major kidney disease event, like losing at least half of their kidney function, or needing dialysis or a kidney transplant. There were 331 such events among the semaglutide group, compared with 410 in the placebo group.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

A major clinical trial showed such promising results that the drug\u2019s maker halted it early.Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic kidney disease in a major clinical trial, the results of which were published on Friday. The findings could transform how doctors treat some of the sickest patients with chronic kidney disease, which affects more than one in seven adults in the United States but has no cure.\u201cThose of us who really care about kidney patients spent our whole careers wanting something better,\u201d said Dr. Katherine Tuttle, a professor of medicine at the University of Washington School of Medicine and an author of the study. \u201cAnd this is as good as it gets.\u201d The research was presented at a European Renal Association meeting in Stockholm on Friday and simultaneously published in The New England Journal of Medicine.The trial, funded by Ozempic maker Novo Nordisk, was so successful that the company stopped it early. Dr. Martin Holst Lange, Novo Nordisk\u2019s executive vice president of development, said that the company would ask the Food and Drug Administration to update Ozempic\u2019s label to say it can also be used to reduce the progression of chronic kidney disease or complications in people with Type 2 diabetes.Diabetes is a leading cause of chronic kidney disease, which occurs when the kidneys don\u2019t function as well as they should. In advanced stages, the kidneys are so damaged that they cannot properly filter blood. This can cause fluid and waste to build up in the blood, which can exacerbate high blood pressure and raise the risk of heart disease and stroke, said Dr. Subramaniam Pennathur, the chief of the nephrology division at Michigan Medicine.The study included 3,533 people with kidney disease and Type 2 diabetes, about half of whom took a weekly injection of semaglutide, and half of whom took a weekly placebo shot.Researchers followed up with participants after a median period of around three and a half years and found that those who took semaglutide had a 24 percent lower likelihood of having a major kidney disease event, like losing at least half of their kidney function, or needing dialysis or a kidney transplant. There were 331 such events among the semaglutide group, compared with 410 in the placebo group.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":6796,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-6794","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lifestyle"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/6794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6794"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/6794\/revisions"}],"predecessor-version":[{"id":6797,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/6794\/revisions\/6797"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/6796"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}